A randomized controlled study of SC-3460 in the treatment of COVID-19

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056817

Enrollment

Unknown

Registered

2022-02-18

Start date

2022-03-03

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:SC-3460

Control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >18 years; 2. SARS-CoV-2 infection was confirmed by PCR with or without COVID-19 related symptoms within 5 days before screening; 3. No gender limit (contraceptive or infertile).

Exclusion criteria

Exclusion criteria: 1. Patients with recurrent COVID-19; 2. History of severe allergic reactions, including generalized urticaria, angioedema, and hypersensitivity; 3. Have received plasma and SARS-CoV-2 antibody treatment during the convalescent period of COVID-19; 4. Have received other investigational drugs for SARS-CoV-2; 5. Pregnant patients; 6. The medical doctor determines that there are any conditions that are not suitable for participation in the program.

Design outcomes

Primary

Measure	Time frame
Percentage of negative nucleic acid tests (Nasopharyngeal swabs/respiratory secretions);	—

Secondary

Measure	Time frame
Clinical prognosis;	—

Countries

China

Contacts

Public ContactLiu Yingxia

Shenzhen Third People's Hospital

yingxialiu@hotmail.com+86 13603096453

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026